Cough, a ubiquitous symptom, necessitates precise clinical characterization to guide appropriate management. Central to this is the fundamental differentiation between acute and chronic presentations. An acute cough is clinically defined as a cough of less than three weeks’ duration, specifically in individuals without a pre-existing diagnosis of asthma and absent “red flag” symptoms such as dyspnea, hemoptysis, or systemic indicators like fever, significant weight loss, or peripheral edema. This temporal and symptomatic delineation is crucial, as its underlying etiology and management paradigms diverge significantly from those of chronic cough, which persists for eight weeks or more.
From a diagnostic perspective, the vast majority—an estimated 90% to 98%—of acute cough cases are attributable to self-limiting viral upper respiratory tract infections (URTIs), typically resolving within 7 to 10 days. This inherent self-resolution often contrasts with patient and, at times, clinician expectations for immediate symptomatic relief.
This brings us to the therapeutic perspective. Despite significant patient reliance on both prescribed and over-the-counter (OTC) medications, the evidence supporting pharmacotherapy for symptomatic relief of acute cough is notably limited. Conventional antitussives, including opioids like codeine or hydrocodone, offer minimal demonstrable benefit and carry substantial side-effect profiles. Similarly, inhaled or oral corticosteroids, inhaled β-agonists or anticholinergics, mucolytics, NSAIDs, first-generation antihistamines, decongestants, and guaifenesin have not consistently shown to decrease illness duration or symptoms in the majority of patients, while concurrently posing risks of adverse effects. A critical safety consideration for experts is the potential for increased serotonin effect when dextromethorphan is co-administered with Selective Serotonin Reuptake Inhibitors (SSRIs), such as sertraline, underscoring the importance of thorough medication reconciliation.
Conversely, the antimicrobial stewardship perspective underscores that antibiotics are unequivocally not indicated for acute cough, given its predominantly viral etiology. Over-prescription of antibiotics contributes directly to antimicrobial resistance, a pressing global health concern.
From an integrated care perspective, the focus for acute viral cough should pivot towards safe, effective, and evidence-based symptomatic interventions. Several studies have validated the clinical benefits of honey for acute viral URTI symptoms in patients over one year of age. Honey possesses inherent antibacterial and antiviral properties, alongside a demonstrated ability to decrease mucus production and cough frequency, all without the systemic side effects associated with many prescription or OTC cough suppressants.
In conclusion, distinguishing acute from chronic cough on the basis of duration and absence of red flags is paramount. While patient expectations for immediate symptomatic relief are understandable, an evidence-based approach dictates a cautious stance on pharmacotherapy for acute viral cough. Prioritizing patient safety, embracing antimicrobial stewardship, and recommending clinically validated, low-risk interventions like honey represent a comprehensive and professional approach to managing this common presentation.
Be the first to comment